Annual report [Section 13 and 15(d), not S-K Item 405]

Acquisitions, Licensing and Other Arrangements - Pulmokine Acquisition (Details)

v3.25.1
Acquisitions, Licensing and Other Arrangements - Pulmokine Acquisition (Details) - USD ($)
$ in Thousands
 12 Months Ended
Nov. 26, 2024
Dec. 31, 2024
Dec. 31, 2023
Asset acquisition      
Amortization of intangible assets   $ 206 $ 897
Impairment of intangible asset     14,253
Allocation of purchase consideration      
Cash and cash equivalents   101,654 153,290
Deferred tax liability   (5,684) (79)
Other assets - long term   1,861 533
Accounts payable   (1,053) (653)
Net Income (Loss)   (13,821) (40,831)
Income and revenues   28,487 4,758
Pulmokine      
Asset acquisition      
Estimated useful life 12 years    
Amortization of intangible assets   200  
Impairment of intangible asset   0  
Purchase consideration      
Closing cash payment $ 19,998    
Holdback amount 100    
Transaction costs 435    
Total purchase consideration 20,533    
Allocation of purchase consideration      
Cash and cash equivalents 357    
Intangible assets 26,115    
Deferred tax liability (5,659)    
Accrued and other liabilities (280)    
Net assets acquired $ 20,533    
Contract assets   0  
Contract liabilities   0  
Capitalized contract costs   0  
Pulmokine | Pro forma      
Allocation of purchase consideration      
Net Income (Loss)   (16,000) (33,000)
Income and revenues   $ 28,500 $ 14,800